{"id":832892,"date":"2025-04-02T08:38:57","date_gmt":"2025-04-02T12:38:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/"},"modified":"2025-04-02T08:38:57","modified_gmt":"2025-04-02T12:38:57","slug":"palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/","title":{"rendered":"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology"},"content":{"rendered":"

\nPresentation to highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN\u2122 rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations
\n<\/h2>\n
\n

WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc.<\/a> (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced a late-breaking oral presentation at the\u00a0upcoming 15th World Congress of Pediatric Dermatology, taking place\u00a0April 8-11, 2025, in\u00a0Buenos Aires, Argentina.<\/p>\n

The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN\u2122 rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations. The details are as follows:<\/p>\n

\n 15th World Congress of Pediatric Dermatology Abstract<\/strong>
\n
\n Title<\/u>: SELVA: A Phase 3 study with a fit-for-purpose primary endpoint evaluating QTORIN\u2122 3.9% rapamycin anhydrous gel in the treatment of microcystic lymphatic malformations in patients 3 years of age and older
Presenter<\/u>: Amy Paller, M.S., M.D., Walter J.\u00a0Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, and Principal Investigator\u00a0of the NIH-funded Skin Biology and Diseases Resource-based Center at Northwestern University’s Feinberg School of Medicine
Session<\/u>: Free Communications VII: Case Series & Clinical or Epidemiological Studies\u00a0
Session Date, Time & Location<\/u>:\u00a0Friday, April 11, 2025 between 8:30-10:00 am GMT-3 in room F<\/p>\n

\n About Microcystic Lymphatic Malformations<\/strong>\n <\/p>\n

Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs is persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States.<\/p>\n

\n About Palvella Therapeutics<\/strong>\n <\/p>\n

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN\u2122 platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella\u2019s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN\u2122 rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com<\/a> or follow Palvella on LinkedIn<\/a> or X<\/a> (formerly known as Twitter).<\/p>\n

QTORIN\u2122 rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.<\/p>\n

\n Contact\u00a0Information<\/strong>\n <\/p>\n

\n Investors<\/u>
\n
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com<\/a><\/p>\n

\n Media<\/u>
\n
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Presentation to highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN\u2122 rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced a late-breaking oral presentation at the\u00a0upcoming 15th World Congress of Pediatric Dermatology, taking place\u00a0April 8-11, 2025, in\u00a0Buenos Aires, Argentina. The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN\u2122 rapamycin 3.9% anhydrous gel for the treatment of … <\/p>\n

Continue reading “Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832892","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPalvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Presentation to highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN\u2122 rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced a late-breaking oral presentation at the\u00a0upcoming 15th World Congress of Pediatric Dermatology, taking place\u00a0April 8-11, 2025, in\u00a0Buenos Aires, Argentina. The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN\u2122 rapamycin 3.9% anhydrous gel for the treatment of … Continue reading "Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T12:38:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology\",\"datePublished\":\"2025-04-02T12:38:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/\"},\"wordCount\":537,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/\",\"name\":\"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=\",\"datePublished\":\"2025-04-02T12:38:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/","og_locale":"en_US","og_type":"article","og_title":"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - Market Newsdesk","og_description":"Presentation to highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN\u2122 rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or \u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced a late-breaking oral presentation at the\u00a0upcoming 15th World Congress of Pediatric Dermatology, taking place\u00a0April 8-11, 2025, in\u00a0Buenos Aires, Argentina. The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN\u2122 rapamycin 3.9% anhydrous gel for the treatment of … Continue reading \"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T12:38:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology","datePublished":"2025-04-02T12:38:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/"},"wordCount":537,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/","name":"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=","datePublished":"2025-04-02T12:38:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU4NiM2ODQ3NDU1IzIxMjMxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-announces-late-breaking-oral-presentation-at-the-15th-world-congress-of-pediatric-dermatology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832892"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832892\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}